

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES

Subject: Fenbuconazole, Quantitative Risk Assessment, Two-

Year Rat (Charles River Sprague-Dawley, MRID Nos. 416353-01 & 416353-02) Dietary

Study

Caswell no.723Q

Hugh M. Pallyners 2/7/94

Genice Fisher 2/2/94

From:

Bernice Fisher, Biostatistician

Statistics Section

Science Analysis Branch

Health Effects Division (7509C)

To:

SanYvette Williams, Pharmacologist

Review Section IV Toxicology *Branch II

Health Effects Division (7509C)

Thru:

Hugh Pettigrew, Ph.D., Section Head


Statistics Section

Science Analysis Branch

Health Effects Division (7509C)

Summary

The unit risk, $Q_1^*(mg/kg/day)^1$ of Fenbuconazole, based upon male rat thyroid follicular cell (adenomas and/or carcinomas) tumor rates is 1.65×10^{-2} (mg/kg/day) in human equivalents. The data on tumor rates and dose levels represent combined data from two rat studies. The dose levels used, from the combined studies were 0, 8, 80, 800 and 1600 ppm. of Fenbuconazole. The corresponding combined tumor rates were 5/113, 5/58, 3/57 13/116, and 10/55 respectively.



Background

In August, 1993 the Peer Review Committee recommended that a quantitative risk assessment for Fenbuconazole be estimated from the combined high and low dose studies of rats for male thyroid follicular (adenomas and/or carcinomas) tumor rates.

The statistical evaluation (Fenbuconazole-Qualitative Risk Assessment-Based on Charles River Sprague-Dawley Rat and CD-1 Mouse Dietary Studies, L.Brunsman 7/93) indicated that there was no significant differential mortality with dose increments of Fenbuconazole in the low dose study and a decrease in mortality (although not statistically significant) in the high dose group. The male rats, both the high and low dose studies had significantly increasing trends in thyroid follicular cell (adenomas and/or carcinomas) tumor rates with dose increments of Fenbuconazole.

Dose-Response

Since mortality did not significantly increase in either of the two rat studies with incremental doses of Fenbuconazole in males, the estimate of the unit risk, Q_1^* was obtained by the application of the Linearized Multi-Stage model (Tox_Risk program, version 3.1- K.Crump).

An estimate of risk, Q₁* was calculated for both the high and low dose studies separately for the thyroid follicular cell (adenomas and/or carcinomas) tumor rates and also for the combined data from both studies for the same tumor rates.

The results of the estimate of unit risk, Q_i are as follows:

Species:Strain,	tumor	0 * (ma/lea/days)-1
Rat:Charles River Sprague-Dawley	Thyroid follicular cell(adenoma &/or	Q _i * (mg/kg/day) ^l in Human Equivalence
Male- low dose	carcinoma)	3.00x10 ⁻²
Male- high dose		1.52x10 ⁻²
Males- combined doses		1.65x10 ⁻²

It is to be noted that Q_l^* (mg/kg/day) is an estimate of the upper bound on risk and that (as stated in the EPA Risk Assessment Guidelines) "the true value of the risk is unknown, and may be as low as zero."